The Lamiaceae family of medicinal plants holds immense promise in the development of functional foods aimed at preventing and treating cardiovascular diseases (CVDs). These plants are rich in bioactive compounds, such as phenolics and flavonoids, which serve as potent enzyme inhibitors and exhibit strong antioxidant and anti-inflammatory properties. Species like Salvia moorcroftiana and Ocimum sanctum have been extensively studied for their beneficial phenolic profiles, contributing to their cardiovascular health benefits. Furthermore, essential oils derived from Lamiaceae herbs have shown significant biological activities, including antihyperlipidemic, vasorelaxant, thrombolytic, and cytotoxic effects, making them valuable components in nutraceutical formulations. In this study, our patent analysis reveals a significant uptick in filings related to Lamiaceae plants for CVD prevention and treatment since the late 1990s, with a peak around 2010. This trend highlights a growing global interest in utilizing these plants within the nutraceutical industry. Leading the patent filings is Tianjin Tasly Pharmaceuticals Co., Ltd., reflecting the active involvement of pharmaceutical companies alongside independent researchers and organizations. Geographically, China emerges as the dominant region for patent activity, followed by the United States and Europe, indicating both strong regional interest and potential market opportunities. These findings align with critical International Patent Classification (IPC) codes, such as A61K36/53 for Lamiaceae, A61P9/00 for cardiovascular drugs, and A61P9/10 for treatments of ischemic or atherosclerotic diseases. This study underscores the significant impact of Lamiaceae plants, not only in advancing cardiovascular health but also in shaping the future of functional foods and nutraceuticals, driven by their rich bioactive profiles and therapeutic potential.